OXiGENE regains compliance for continued listing on NASDAQ Global Market

Download PDF Copy

Apr 7 2010

NewsGuard 100/100 Score

OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has received a letter from NASDAQ Global Market exchange confirming that, with the appointment of Tamar Howson to the Company's audit committee, as detailed in the Company's Form 8-K filed on April 5, 2010, NASDAQ staff has determined that the Company complies with Listing Rule 5605(c)(2) requiring the Company to have at least three independent directors on its audit committee for continued listing on the NASDAQ Global Market, and this matter is now closed.

Source:

OXiGENE

Posted in:

Tags: Biopharmaceutical, Cancer, Eye, Eye Disease, Pharmaceuticals, Therapeutics

Comments (0)

Download PDF Copy

Suggested Reading

AI-powered tool predicts gene activity in cancer cells from biopsy images

AI-powered tool predicts gene activity in cancer cells from biopsy images

Female firefighters face elevated breast cancer risks due to toxic exposures

Female firefighters face elevated breast cancer risks due to toxic exposures

Golgi apparatus plays crucial role in enhancing T-cell function against cancer

Golgi apparatus plays crucial role in enhancing T-cell function against cancer

Researchers uncover key genes linked to DCIS progression

Researchers uncover key genes linked to DCIS progression

Study shows AI can predict prognosis in triple-negative breast cancer

Study shows AI can predict prognosis in triple-negative breast cancer

Study shows cannabis as a genotoxic substance with cancer risks

Study shows cannabis as a genotoxic substance with cancer risks

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients

Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Scientists map cancer mutations in EGFR gene, revealing drug resistance paths